Potentially Ground-Breaking Vaccines, Therapeutics for Crimean-Congo Hemorrhagic Virus

Despite the fact that between 10% and 40% of Crimean-Congo hemorrhagic fever cases are fatal, there is little known about the mechanism that the body uses to counteract the virus and the structure of the neutralizing antibodies involved in this process. Researcher at the U.S. Department of Energy’s Advanced Photon Source, the European Synchrotron Radiation Facility, and the French SOLEIL synchrotron provide new insights for protection against this contagious and often fatal virus.